bmiMD Review

A published ladder, which is rarer than it should be

bmiMD sells compounded semaglutide and compounded tirzepatide on a ladder keyed to plan length. Each longer prepaid term buys a lower monthly rate than the one below it. Within any chosen term, the rate does not move as the dose increases. There is also a newer lower-dose product line priced on the same structure.

What makes this worth writing about is not the ladder itself — plenty of providers discount for commitment. It is that bmiMD publishes the rungs. A reader can see what each term costs and do the arithmetic before handing over a card, instead of discovering the structure at checkout after an intake. The most common pricing pattern in this category is a single 'starting at' figure with the conditions buried. A legible ladder is a genuine courtesy.

It is also a device that works on the reader. A ladder is designed to make the longest term look obviously correct, and it usually does — right up until month four, when something changes. Read the rungs as what they are: a discount offered for accepting risk the provider would otherwise carry.

The commitment, and the fee attached to leaving

The bottom rung of bmiMD's ladder is reached only by prepaying a full year. Billing on a monthly basis lands well above it. That is the trade in plain terms. The qualifier printed beside each figure carries the specific plan term that figure belongs to, because a bmiMD number quoted without its term is not a price. It is half of one.

There is a second condition that matters more than its size suggests. A non-refundable fee applies if a patient cancels after intake has been approved. It is disclosed, and it is not large relative to the cost of treatment. It is also the kind of term that reads as trivial when signing up and irritating when leaving. Combined with a prepaid annual term, it makes bmiMD a provider to choose deliberately rather than to try out.

The counterweight is real. bmiMD says the charge taken at checkout is only an authorization hold, and that nothing is collected if a provider turns the patient down. That addresses the most common complaint in this category: being charged before anyone has confirmed you are eligible for the medication. A reader who does not clear intake should not be out of pocket.

Who is actually behind the brand

bmiMD discloses that it is operated by Medccm Inc. That sounds like a small thing and is not. A meaningful share of telehealth GLP-1 brands are marketing names attached to an entity a customer cannot identify. That leaves a patient unable to look up who they are dealing with, what else that entity operates, or where to send a complaint that goes past customer service. bmiMD tells you. Several providers in this comparison do not.

bmiMD also maintains a public third-party review profile on Trustpilot, rather than relying only on testimonials selected and hosted on its own site. That is not a quality score. A public review profile is a place to read complaints, not a rating worth endorsing. Even so, an outside venue where dissatisfied customers can be read is worth more to a prospective patient than a page of curated quotes.

The gap: the pharmacy is never named

bmiMD never identifies the pharmacy that compounds and dispenses what a patient injects. On a compounded medication, that is the disclosure a reader would most want. The contrast with everything else bmiMD publishes makes the omission more conspicuous, not less. A company willing to name its operating entity and print its price ladder has clearly decided where its transparency stops.

Everything in this category at bmiMD is compounded. Compounded semaglutide and tirzepatide are prepared by a compounding pharmacy and are not FDA-approved finished drug products. bmiMD does not publish a brand-name option. That distinction is the substance of the price difference between this provider and a brand-name route, and it should not be flattened into a comparison of two numbers.